Benchmark/techtransfer.nih.gov/Discovery to Commercialization: New Immunotherapy for Rare Childhood Cancer, Neuroblastoma
Discovery to Commercialization: New Immunotherapy for Rare Childhood Cancer, Neuroblastoma
www.techtransfer.nih.gov/kudo/discovery-to-commercialization-new-immunotherapy-fother404 mots
73.6GEO Score
Correct : marge d'amélioration
Moyenne du domaine : 85.8
Signaux de citabilité
Forces
Densité de citations
94
Naturalité
82
Sources citées
77
Diversité du contenu
74
À renforcer
Optimisation Q&R
55
Qualité structurelle
20
Autorité réelle des sources
Le classement d'autorité de chaque source citée (au-delà du regex) et le plan d'action détaillé, dans Citead.
Toutes les pages de techtransfer.nih.gov
A Low-Cost Tissue Microarrayer Instrument to Support Improved Cancer Diagnoses
otherDevelopment of First Immunotherapy to Treat Chordoma
otherDevelopment of First Immunotherapy to Treat Chordoma, a Rare Bone Cancer
otherInterleukin-2 Receptor Gamma Deficient Mice, Widely Used Research Tools
otherNovel Therapeutics to Treat Niemann-Pick C Disease and Other Lysosomal Disorders
other